Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 act mut Dovitinib endometrial cancer sensitive detail...
Unknown unknown Everolimus endometrial cancer not applicable detail...
Unknown unknown Pegylated liposomal-doxorubicin + Temsirolimus endometrial cancer not applicable detail...
Unknown unknown BEZ235 endometrial cancer not applicable detail...
Unknown unknown Sunitinib endometrial cancer not applicable detail...
Unknown unknown Adavosertib + Paclitaxel endometrial cancer not applicable detail...
FGFR2 mutant Infigratinib endometrial cancer sensitive detail...
PIK3CA mutant CH5132799 endometrial cancer sensitive detail...
PIK3CA H1047Y CH5132799 endometrial cancer sensitive detail...
FGFR2 C383R FGFR2 N550K PD173074 endometrial cancer resistant detail...
FGFR2 N549K Ponatinib endometrial cancer sensitive detail...
FGFR2 N549K Dovitinib endometrial cancer decreased response detail...
FGFR2 N549K Cediranib endometrial cancer sensitive detail...
FGFR2 N549K Nintedanib endometrial cancer resistant detail...
FGFR2 N549K Brivanib endometrial cancer no benefit detail...
FGFR2 S252W Ponatinib endometrial cancer sensitive detail...
FGFR2 S252W Cediranib endometrial cancer sensitive detail...
FGFR2 S252W Brivanib endometrial cancer sensitive detail...
FGFR2 S252W Nintedanib endometrial cancer sensitive detail...
FGFR2 wild-type Ponatinib endometrial cancer resistant detail...
FGFR2 S252W Dovitinib endometrial cancer decreased response detail...
FGFR2 - BICC1 FGFR2 - OFD1 Erdafitinib endometrial cancer predicted - sensitive detail...
FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N549K Debio 1347 endometrial cancer sensitive detail...
FGFR2 S252W Debio 1347 endometrial cancer sensitive detail...
PIK3CA mutant Pictilisib endometrial cancer sensitive detail...
PIK3CA mutant GDC-0980 endometrial cancer sensitive detail...
AKT1 mutant GDC-0980 endometrial cancer sensitive detail...
ALK wild-type Dalantercept endometrial cancer no benefit detail...
STK11 inact mut Sirolimus endometrial cancer sensitive detail...
Unknown unknown GSK2126458 endometrial cancer not applicable detail...
SF3B1 K666N Spliceostatin A endometrial cancer sensitive detail...
AKT1 mutant Temsirolimus endometrial cancer predicted - sensitive detail...
CTNNB1 mutant Temsirolimus endometrial cancer predicted - sensitive detail...
PIK3CA mutant Temsirolimus endometrial cancer no benefit detail...
HRAS mutant Trametinib endometrial cancer sensitive detail...
Unknown unknown Everolimus + Letrozole + Metformin endometrial cancer not applicable detail...
FGFR2 mutant PRN1371 endometrial cancer sensitive detail...
FGFR2 K310R FGFR2 N550K AZD4547 endometrial cancer sensitive detail...
FGFR2 N550K AZD4547 endometrial cancer decreased response detail...
FGFR2 S252W AZD4547 endometrial cancer decreased response detail...
FGFR2 over exp AZD4547 endometrial cancer resistant detail...
FGFR2 wild-type AZD4547 endometrial cancer resistant detail...
FGFR2 amp AZD4547 endometrial cancer sensitive detail...
FGFR2 S252W E7090 endometrial cancer sensitive detail...
Unknown unknown Cediranib endometrial cancer not applicable detail...
AKT1 E17K Miransertib endometrial cancer sensitive detail...
AKT1 E17K ARQ 751 endometrial cancer sensitive detail...
Unknown unknown ETP-46464 + Radiotherapy endometrial cancer not applicable detail...
Unknown unknown Cisplatin + ETP-46464 endometrial cancer not applicable detail...
Unknown unknown Cisplatin + VE-821 endometrial cancer not applicable detail...
AKT1 E17K Capivasertib endometrial cancer predicted - sensitive detail...
Unknown unknown ONC201 endometrial cancer not applicable detail...
Unknown unknown Capivasertib + Olaparib endometrial cancer not applicable detail...
ERBB2 mutant Neratinib endometrial cancer no benefit detail...
ERBB2 P761del Neratinib endometrial cancer predicted - resistant detail...
ERBB2 R678Q Neratinib endometrial cancer no benefit detail...
ERBB2 S310F Neratinib endometrial cancer predicted - sensitive detail...
ERBB2 S310Y Neratinib endometrial cancer no benefit detail...
ERBB2 V697L Neratinib endometrial cancer predicted - resistant detail...
ERBB2 V777L Neratinib endometrial cancer predicted - sensitive detail...
ERBB2 V842I Neratinib endometrial cancer predicted - resistant detail...
FGFR2 S252W Derazantinib endometrial cancer sensitive detail...
FGFR2 N549K Derazantinib endometrial cancer sensitive detail...
PIK3CA mutant Alpelisib endometrial cancer sensitive detail...
Unknown unknown Lenvatinib + Pembrolizumab endometrial cancer not applicable detail...
Unknown unknown Trametinib + Uprosertib endometrial cancer no benefit detail...
Unknown unknown Cabozantinib endometrial cancer not applicable detail...
CTNNB1 mutant Cabozantinib endometrial cancer predicted - sensitive detail...
Unknown unknown LY3023414 endometrial cancer not applicable detail...
PIK3CA mutant MK2206 endometrial cancer no benefit detail...
ARID1A mutant unspecified PD-L1 antibody endometrial cancer predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody endometrial cancer predicted - sensitive detail...
PIK3CA mutant Perifosine endometrial cancer not predictive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01379534 Phase II Dovitinib A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed
NCT01697566 Phase III Metformin An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting
NCT01797523 Phase II Letrozole Everolimus Metformin RAD/Letrozole/Metformin Active, not recruiting
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting
NCT01935934 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting
NCT02035787 Phase I Metformin Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Recruiting
NCT02042495 Phase II Metformin Endometrial Cancer Biomarker Changes Following Exposure to Metformin Withdrawn
NCT02188550 Phase II Everolimus + Letrozole Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Active, not recruiting
NCT02630823 Phase I Carboplatin + Paclitaxel + Pembrolizumab MK-3475 Immunotherapy in Endometrial Carcinoma Active, not recruiting
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer Active, not recruiting
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated
NCT02684227 Phase II Carboplatin + Enzalutamide + Paclitaxel Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer Recruiting
NCT02715284 Phase I Dostarlimab A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting
NCT02728258 Phase II Copanlisib Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Active, not recruiting
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Active, not recruiting
NCT02788708 Phase I Lenvatinib + Paclitaxel Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Active, not recruiting
NCT02899793 Phase II Pembrolizumab Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Active, not recruiting
NCT02912572 Phase II Avelumab + Talazoparib Avelumab Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer Recruiting
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT03016338 Phase II Niraparib Study of Niraparib in Recurrent Endometrial Cancer Recruiting
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03099499 Phase II ONC201 Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer Recruiting
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03300557 Phase II Exemestane Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer Recruiting
NCT03310567 Phase II Epacadostat + Pembrolizumab A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma Withdrawn
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03474640 Phase I Toripalimab Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Recruiting
NCT03485729 Phase II ONC201 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Recruiting
NCT03508570 Phase I Nivolumab Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting
NCT03555422 Phase III Selinexor Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Active, not recruiting
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Active, not recruiting
NCT03617679 Phase I Rucaparib Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03643510 Phase II Abemaciclib + Fulvestrant Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03675893 Phase II Abemaciclib + LY3023414 Abemaciclib + Letrozole + LY3023414 A Phase 2 Study of LY3023414 and Abemaciclib With or Without Letrozole in Endometrial Cancer Recruiting
NCT03748186 Phase I STRO-002 Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Recruiting
NCT03835819 Phase II Mirvetuximab Soravtansine + Pembrolizumab A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Suspended
NCT03968406 Phase I Talazoparib Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Recruiting
NCT03981796 Phase III Carboplatin + Paclitaxel Carboplatin + Dostarlimab + Paclitaxel A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) Recruiting
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT04122625 Phase Ib/II Debio 1143 + Nivolumab Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Recruiting
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Not yet recruiting
NCT04214067 Phase III Pembrolizumab Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Recruiting
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Not yet recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting